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Abstract
F18 2-Fluoro 2-deoxyglucose (FDG) has been the gold standard in positron emission tomography (PET) oncologic imaging
since its introduction into the clinics several years ago. Seeking to complement FDG in the diagnosis of breast cancer using
radio labeled fructose based analogs, we investigated the expression of the chief fructose transporter-GLUT 5 in breast
cancer cells and human tissues. Our results indicate that GLUT 5 is not over-expressed in breast cancer tissues as assessed by
an extensive immunohistochemistry study. RT-PCR studies showed that the GLUT 5 mRNA was present at minimal amounts
in breast cancer cell lines. Further knocking down the expression of GLUT 5 in breast cancer cells using RNA interference did
not affect the fructose uptake in these cell lines. Taken together these results are consistent with GLUT 5 not being essential
for fructose uptake in breast cancer cells and tissues.
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Introduction
Breast cancer is the second leading cause of cancer deaths in
women today and is the most common form of cancer among
women excluding non-melanoma skin cancers. The World Health
Organization estimated that worldwide, in excess of 1.2 million
people were diagnosed with breast cancer in 2005 [1]. Breast
cancer cells have a high level of glucose uptake and metabolism, a
common characteristic of most cancer cells. This increased glucose
uptake and aerobic metabolism forms the basis for assessment of
tumor metabolism and response to therapy by positron emission
tomography (PET) imaging with FDG (F-18 2-fluoro-29-deox-
yglucose) [2,3,4]. Due to poor imaging of noninvasive breast
cancer [5],
18FDG-PET has been mostly performed on invasive
breast cancer. The success of
18FDG-PET for the initial detection
and diagnosis of primary breast cancer varies greatly [6], which is
mainly attributed to different metabolism levels in different types
of tumors, e.g. infiltrating ductal carcinoma has a higher level of
18FDG uptake than infiltrating lobular breast cancer. Also, the
staging of axillary lymph nodes with
18FDG-PET has produced
mixed results. Patients with invasive breast cancer routinely
undergo lymphoscintigraphy and axillary lymph node dissection
(ALND). Sentinel node biopsies (SNB) are also performed.
Comparison of these methods with
18FDG-PET shows very
different sensitivities and specificities for
18FDG-PET, usually (but
not always) with higher sensitivity and lower specificity, and many
recent studies suggest that
18FDG-PET may not have a sufficiently
high negative predictive value to justify forgoing ALND. One
reason is the difference in minimal size of the lesion that can be
detected. Even with modern clinical PET systems the limit of
spatial resolution is approximately 6.0 mm, which is consistent
with the results that
18FDG activity was very low or non-detectable
in patients with tumors sizes ranging from 0.4 to 1.5 cm.
Glucose, galactose and fructose serve as basic fuel molecules for
many cells, and these molecules require transporters for entry and
exit from those cells. Three distinct groups of hexose transporters
have been identified and classified based on their dependence on
cellular energy [7,8]. The first class of transporters, GLUT1-4 is
primarily glucose transporters with distinct tissue distributions. The
presence of the GLUT1 transporter is important for the imaging of
tumor and inflammatory tissues with FDG because FDG is
transported mainly by GLUT1. The second class of transporters
is exemplified by GLUT5, GLUT7, GLUT9 and GLUT11 all of
which are previously known fructose transporters. Uptake of
fructose is thought to be mediated mainly through GLUT5, and
based on similarity of the different isoforms within this class;
GLUT7, GLUT9 and GLUT11 are also fructose transporters.
GLUT5 does not transport glucose and is expressed mainly in small
intestine, sperm cells and brain with very low level expression in
muscle and adipose tissue. GLUT5 transports fructose with high
affinity. At normally low physiological concentrations of fructose in
vivo, GLUT5 likely mediates .90% of fructose uptake owing to the
order of magnitude difference in respective Km values for GLUT5
and the other fructose transporters. The remainder of the
transporters represents the third class of GLUT transporters, which
are largely as yet uncharacterized with limited knowledge regarding
exact cellular functions.
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tissue specific expression and response to metabolic and hormonal
regulation [9]. Although a number of different isoforms of GLUT
have been identified, they all appear to share a common membrane
topology possessing a large highly conserved transmembrane
domain, with less conserved assymetric-membrane cytoplasmic
and exoplasmic domains [10]. The transmembrane domain is
composed of twelve membrane-spanning helices containing a water
filled pathway through which the substrate moves [11,12]. The
cytoplasmic domain contains a short N-terminal segment, a large
cytosolic loop and a large C-terminal segment. The exoplasmic
domain consists of a large loop structure bearing a single N-linked
oligosaccharide moiety. Isoform specific amino acid sequences are
found in the cytoplasmic and exoplasmic domains indicating that
they are responsible for tissue-specific regulation of transporter
function. The primary structure of the transmembrane domain is
largely conserved, suggesting that the glucose channel is essentially
identical in structure among the different isoforms.
Localization, expression and regulation of the GLUT family
members are tissue and cell-specific. As new GLUT isoforms are
continually being discovered and characterized in various cell
types, their involvement in disease states is under constant review.
In cancer cells, which have broken free from the normally tight
biochemical regulation, aberrant expression of the GLUT family
members is often observed, presumably to help provide the energy
required for further uncontrolled proliferation and metastasis.
It has been well established that the GLUT1 transporter is highly
expressed in breast cancer cells compared to normal counterparts
[13]. Vera and co-workers [14] have analyzed expression and
function of glucose transporters in breast cell lines (MCF-7 and
MDA-MB-468) and in normal and neoplastic human breast tissue.
According to their results in addition to GLUT1, human breast
tissue selectively expresses the high affinity fructose transporter
GLUT5. Another report by the same group further substantiated
this claim by performing an extensive immunohistochemistry study
in 33 breast tissues samples (representing invasive ductal carcinoma)
[15]. Knocking down GLUT5 by antisense RNA seemed to inhibit
the proliferation of MCF7 and MDA-MB-231 cells [16]. It has also
been demonstrated that several different cancer cell lines, including
breast cancer, melanoma, Caco-2 (colonic cancer) and leukemia
over-express active GLUT5 transporters (15).
While GLUT1 is over-expressed in breast cancer and present in
normal breast, as per the references cited above GLUT5 is largely
absent in normal tissue with high expression levels in human
breast cancer tissue. Hence, specific substrates that are either
transported by GLUT5 or retained and/or inhibitors of fructose
transport with high affinity for GLUT5 should be more effective
imaging agents than those targeting GLUT1.
In this report we have tried to validate the expression of GLUT
5 in the breast cancer cell lines-MCF7 and MDA MB 468
(previously reported to express GLUT 5) and in patient breast
cancer tissues with the intention of exploring the possibility of
using radiolabeled fructose or fructose analogs as PET tracers.
Our results indicate that there is no over-expression of GLUT5 in
breast cancer cells and patient breast cancer tissues as previously
reported. The possible reasons for the discrepancy in observations
are discussed and some crucial experiments that would be essential
to understand the utility of fructose based tracers for breast cancer
imaging are also mentioned in the discussion.
Materials and Methods
Cell culture and siRNA transfections
MDA-MB-468 and MCF 7 cells were grown as per ATCC
(American Type Culture Collections) conditions in Leibovitz L15
and RPMI 1640 respectively. The former needs to be cultured in
the absence of CO2. Stealth siRNA (short-interfering RNA)
against GLUT 5 (accession no: NM_003039) were ordered from
Invitrogen. Three different siRNA against GLUT 5 were obtained
and tested. Negative control siRNA was also ordered from
Invitrogen. RNAimax (transfection reagent) from Invitrogen was
used to reverse- transfect the siRNA into MCF7 and MDA-MB-
468 cells. In brief, 10 nM of the GLUT 5 specific siRNA and
40 nM of the negative control were mixed with the appropriate
amount of Lipofectamine RNAimax in Optimem (serum free
media, Invitrogen) and added to the wells (either 24 well or 6 well
dishes as needed), where they were allowed to incubate for
20 mins at room temperature. The cells were then counted,
diluted (50,000 cells/500 ml) in antibiotic free media and added to
the wells containing the siRNA-lipofectamine mixture. The cells
were incubated for 48 hrs before assaying for knockdown.
Cell uptake studies
2610
5 cells (per well) were plated in a 24-well plate 24 hrs before
the assay in normal growth media. After removing the media, 1 mCi
of either C14-fructose (97% pure, 250–360 mCi/mmol) or C14-
glucose(98% pure, 50–60 mCi/mmol) (Moravek Chemicals, La
Brea, California) was added to each well in HBSS (Hank’s buffered
saline solution or PBS (Phosphate buffered saline) buffers as
required by the assay, and incubated for the specified time points
in a 37uC incubator. The HBSS buffer has 5 mM glucose
(physiological levels) in addition to salts. After the incubation, cells
were washed twice with cold PBS and 500 ml of 0.1N Sodium
Hydroxide was added to the wells to lyse the cells. 10 ml of the
liquid scintillation cocktail was added to 250 ml of the lysate and the
vials placed in a liquid scintillation counter for determining the cell
associated radioactivity. 50 ml of the lysate was used for determining
the protein concentration using Bradford assay.
RNA extraction and analysis
Total RNA was extracted from the cells using the Qiagen
RNeasy kit following the manufacturer’s instructions. An aliquot
of the extracted RNA was subjected to DNase I treatment
(Invitrogen), and the DNase I treated RNA was used to synthesize
cDNA. This cDNA was then used for both qualitative RT-PCR
(using GoTaq PCR master mix, Promega) and quantitative real-
time PCR (Qiagen Sybr Green mix). The primers used were as
follows:
GLUT 5 FW: tcgtgcctgcgatcttaatg
GLUT 5 BW: cagccatctacgtttgcaag
Actin FW: ggtcatcttctcgcggttggccttgg
Actin BW: ccccaggcaccagggcgtgat
Immunohistochemistry
The study was performed by LifeSpan (Seattle, WA) and used full
slides of normal breast (n=10), mastitis (n=10), infiltrating lobular
carcinoma with benign tissue (n=10) and a breast carcinoma tissue
microarray (n=40, LS-SBRCA1). For screening normal tissues a
tissue microarray from LifeSpan was used (LS-SNL2), containing
duplicate specimens each of normal human adrenal, bladder, brain
cortex, breast, colon, heart, kidney cortex, kidney medulla, liver,
lung, ovary, pancreas, placenta, prostate, skeletal muscle, skin, small
intestine, spleen, stomach, testis, thymus, thyroid, tonsil, and uterus.
Antibody GLUT 5 (Abcam, catalog #AB36057 demonstrated the
highest signal-to-noise ratio at a concentration of 10 ug/ml on
formalin-fixed, paraffin embedded tissues. Antibody GLUT 5 was
used as the primary antibody, and the principal detection system
consisted of a Vector anti-rabbit secondary (BA-1000) and a Vector
ABC-AP kit (AK-5000) with a Vector Red substrate kit (SK-5100),
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also stained with positive control antibodies (CD31 and vimentin) to
ensure that the tissue antigens were preserved and accessible for
immunohistochemical analysis. The negative control consisted of
performing the entire immunohistochemistry procedure on adjacent
sections in the absence of primary antibody. Slides were imaged with
a DVC 1310C digital camera coupled to a Nikon microscope.
Statistical analysis
Online statistical analysis tools from GraphPad software were
used for our statistical analysis. An unpaired t-test using mean,
SEM (standard error of mean) and N (number) was done to
calculate a two-tailed P value.
Ethics Statement
The immunohistochemistry study carried out at LifeSpan is
done on patient tissue samples that are provided to LifeSpan by a
source unknown to us. LifeSpan obtains human samples from a
variety of third party sources including hospital pathology
departments and organ donor organizations (not directly organ
donors). Each source complies with IRB approved protocols and
patient consent release policies appropriate for that source. All
tissues acquired by Lifespan have been cleansed of patient
identifiers prior to receipt by LifeSpan to preserve confidentiality.
Results
GLUT 5 expression in breast cancer cell lines
GLUT 5 expression in the MCF7, MDA-MB4-68 and
MCF10A cell lines was evaluated at the mRNA level by
quantitative real-time PCR. The latter-MCF10A is an immortal-
ized breast epithelial cell line often used by researchers as ‘normal’
control for breast cells. As observed in Fig 1A, the MCF 10A cell
line had the highest levels of GLUT 5 mRNA. Both MCF7 and
MDA-MB-468 cell lines had low levels of GLUT5 mRNA. A
representative gel picture is shown in Fig 1B.
Fructose uptake in breast cancer cell lines
MCF7, MDA-MB-468 and MCF10A cells were incubated with
C14 glucose and C14 fructose for 10 mins, to examine the relative
uptake of both tracers. The uptake was done in HBSS buffer which
has physiological levels of glucose (5 mM). Under these conditions,
the cancer cell lines-MCF7 and MDA-MB-468 take up more of the
sugars as compared to the normal MCF10A cell line (Fig 2). The
uptake of both sugars in MCF7 and MCF10A is comparable, but
theMDA-MB-468takesupsignificantly moreoftheC14fructoseas
compared to the C14 glucose (p,0.0001). This result is in contrast
to the mRNA expression data shown in Fig 1, where the MCF10A
cell line had the highest levels of the GLUT5 mRNA. The above
Figure 1. GLUT 5 mRNA levels by quantitative real time PCR. RNA from MCF7, MDA MB 468 and MCF10A were extracted, converted to cDNA
and quantified by real time PCR (fig 1A) and the products also visualized on a 1% agarose gel (fig 1B).
doi:10.1371/journal.pone.0026902.g001
GLUT 5 Expression in Breast Cancer
PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e26902two experiments gave us the first hint that there was no correlation
between the level of GLUT 5 mRNAand the fructose uptake across
the breast cancer cell lines that we tested.
siRNA knockdown of GLUT 5 in breast cancer cell line
siRNA were designed against the GLUT 5 mRNA. The GLUT
5 specific siRNA and a non-specific negative control siRNA were
transfected into MCF7 cells. 48 hrs after transfection, lysates were
prepared for RNA analysis. Quantitative RT-PCR showed that
the GLUT 5 mRNA levels had been knocked down by 59% (Fig 3).
In parallel fructose uptake was evaluated at 48 hrs. post-
transfection in the transfected and non-transfected cells. As shown
in Fig 3, there was no significant change in the fructose uptake
(p=0.46) although the GLUT 5 mRNA had been knocked down.
These experiments thus indicate that GLUT 5 may not be
essential for fructose transport into these breast cancer cell lines
contrary to what has previously been reported by Vera et al [14].
Cytochalasin B treatment blocks fructose transport into
MDA-MB468 cells
The alkaloid Cytochalasin B is a known inhibitor of hexose
transport via GLUT 1, 2, 3 and 4 through its actions on the
cytoskeleton. However fructose transport through GLUT 5 is
insensitive to cytochalasin B treatment [17]. MDA-MB-468 cells
were treated with 100 uM of cytochalasin B and the uptake of C14
fructose and C14 glucose was evaluated in the presence/absence
of cytochalasin B (Fig 4). The glucose uptake was blocked by about
34% (p= 0.0004) and the fructose uptake was blocked by about
35% (p=0.0002). Since the fructose uptake was sensitive to
cytochalasin B treatment, this indicates that fructose uptake in
MDA-MB-468 cells does not rely solely on GLUT5.
Immunohistochemistry
We wanted to evaluate GLUT5 expression in normal vs. breast
cancer tissue samples. The study evaluated GLUT5 expression in
full slides in normal breast (n=10), mastitis (n=10), infiltrating
lobular carcinoma with benign tissue (n=10) and GLUT5
expression in a breast carcinoma tissue microarray (n=40).
In breast tissue samples of benign breast, glandular epithelium
showed positive cytoplasmic and slightly weaker nuclear staining.
Occasionally, mast cells and plasma cells were also positive. In
samples of breast with mastitis (data not shown), glandular
epithelium and the surrounding myoepithelial cells showed slightly
less intense staining in most samples compared to normal samples.
Figure 2. Glucose and Fructose are both taken up by breast cancer cell lines. MCF 7 and MDA MB 468 (breast cancer cell lines) and MCF10A
(breast epithelial cell line) were incubated with 1 mCi each of C14 glucose and C14 fructose for 10 mins in HBSS buffer. The activity associated with
the cells was counted and normalized to activity in the media and to total protein mass associated with the cells. * Indicates p,0.0001 as determined
by an unpaired student t-test described in methods. The error bars represent S.E.M of triplicates.
doi:10.1371/journal.pone.0026902.g002
Figure 3. Knocking down GLUT 5 mRNA in MCF7 cells has no effect on fructose uptake. GLUT 5 specific siRNA and negative control siRNA
were transfected into MCF7 cells. 48 hrs after transfection cells were simultaneously interrogated for both mRNA levels (using quantitative real time
PCR) (right Y axis) and for fructose uptake (left Y axis) by incubating with C14 labeled fructose. The error bars represent S.E.M of triplicates.
doi:10.1371/journal.pone.0026902.g003
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plasma cells, and weaker staining was present in macrophages and
giant cells, but most neutrophils were negative. In breast tissue
samples containing infiltrating lobular carcinoma with surrounding
benign breast tissue (Fig 5), most samples showed weak staining in
malignant cells and endothelium. Staining often appeared to be
slightly more intense in benign glands compared to malignant cells.
There was no differential staining in vessels, inflammatory cells,
stroma,orentrappedbenignepitheliuminareasoftumorcompared
to adjacent benign areas. In a panel of breast carcinomas consisting
of small cores of tissue taken from regions of tumor, most samples
showed weak staining in malignant cells (see Table 1).
A normal tissue microarray (n=2 per tissue) was also examined
for GLUT5 expression (Fig 6). In the normal tissues, the most
significant staining was identified in renal proximal convoluted
tubules and erythrocytes. Prominent staining was also present in
occasional macrophages, lymphocytes, gastrointestinal neuroen-
docrine cells, the adrenal cortex, and microglia in the brain.
Occasionally, positive membranous and perinuclear staining was
present in intestinal epithelium and pancreatic ducts. Less intense
or focal staining was also identified in cardiomyocytes, breast
epithelium, colonic glandular epithelium, brain neurons, hepato-
cytes, ovarian follicles, and thyroid follicular epithelium. Staining
was particularly weak or absent in skin, pancreatic acini and islets,
and placental villi, which helps to confirm the specificity of this
antibody and distinguish this target from GLUT1, which would be
expected to be positive in these tissues.
Discussion
In this report we tried to validate the expression of the fructose
transporter-GLUT5 in breast cancer cells and patient tissues. Our
work was based on the observations of Zamore-Leon et. al. who
previously reported specific expression of the GLUT5 in primary
breast cancer tissues (n=20) with no staining observed in normal
mammary tissue [14]. Interestingly an erratum was published as a
follow up later that year that said their statement ‘no staining in
normal mammary tissue’ was not correct and that they did observe
some staining in normal tissue [18]. A second publication by
Godoy et. al. [15] also detected GLUT 5 in human breast ductal
carcinoma (n=33). However they also reported weak to moderate
staining in normal breast tissue. An important observation though
was that in contrast to GLUT1 which localized to the plasma
membrane, all of the samples which were positive for GLUT5
showed cytoplasmic staining. This may indicate that the GLUT5
may need to be activated to localize to the plasma membrane.
Two other publications that investigated GLUT5 expression by
immunohistochemistry [13,19] reported weak to no staining in
neoplastic breast tissues. Our own results do not support the
observation by Zamore-Leon et. al. (Fig 5 and 6). We did not
observe any significant over-expression of GLUT5 in breast
cancer tissue. While one could attribute the differences to the use
of different antibodies, in our study (conducted in collaboration
with Lifespan Inc.) we tested two different antibodies in phase I
after which one was chosen for phase II IHC staining of the actual
breast tissues. Interestingly we found inter-sample variability with
some tumors showing higher expression and other tumors showing
lower expression, but within a sample containing both normal
breast and breast tumor tissue GLUT5 expression showed no
significant differences between normal breast and breast tumor
tissue. We also observed moderate staining in immune cells which
would argue against the presumption that fructose may be
preferentially taken up by breast cancer cells. The human protein
atlas (www.proteinatlas.org) which is a free online database of IHC
studies available to researchers, stated that ‘‘most malignancies
displayed negative or weak immunoreactivity in some cells’’ for
GLUT5 [20]. In further support of our IHC results, an
examination of GLUT 5 mRNA levels by microarray analysis
did not show a significant difference between breast cancer tissue
and normal breast tissues (data not shown).
While our immunohistochemistry data shows no evidence to
indicate that GLUT5 is greatly over-expressed in breast cancer
tissues, we do see fructose uptake in the breast cancer cells lines-
MCF7 and MDA-MB 468, in contrast to the immortalized breast
epithelial cell line-MCF10A (see Fig 2). This could indicate that
fructose itself could be a marker that distinguishes breast cancer
cells from normal cells. A recent report by Sreekumar et al showed
that fructose was one of the metabolites that came up in a large
scale metabolomics study of prostate cancer tissue differentiating
benign from PCAs [21]. Moreover work from our own lab has
Figure 4. Cytochalasin B treatment affects fructose uptake in MDA MB 468 cells. MDA MB 468 cells were exposed to 100 mM cytochalasin B
for 30 mins. Then 1 mCi of C14 fructose or glucose was added to the cells, and the uptake was continued for 10 mins in HBSS. The activity associated
with the cells was then counted and normalized to activity in the medium and to total protein mass. * indicates p values ,0.05. The error bars
represent S.E.M of triplicates.
doi:10.1371/journal.pone.0026902.g004
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taken up by breast cancer cells [22].
This uptake of fructose in the breast cancer cell lines-MCF7 and
MDA MB 468- was sensitive to cytochalasin B (Fig 4) –a potent
inhibitor of glucose uptake by GLUT1[17]. Fructose uptake by
GLUT5 on the other hand should not be affected by cytochalasin
B [17,23] but it was. Further knocking down GLUT5 expression
by RNA interference also did not affect fructose uptake (Fig 3).
The fructose uptake in the cell lines also did not correlate to
GLUT5 mRNA levels (Fig 1 and 2). All these experiments are
consistent with the possibility that fructose uptake in the breast
cancer cell lines MCF7 and MDA-468 is not solely dependant on
GLUT5 expression. A limitation of the current study is the lack of
western blotting data showing protein expression or lack of in the
MCF 7 and MDA MB 468 cells. We did attempt western blotting
with different GLUT5 antibodies but were unable to see a clear
band of the right size in MDA-MB 468 cells (data not shown). We
did however see some bands in the MCF 7 cells. Since our focus
was to evaluate GLUT5 expression in tissue sections by IHC we
did not further pursue the western blotting.
In this study we did not study the expression of other fructose
transporters (GLUT 2, GLUT 7 and GLUT 11) in breast cancer
tissues or cell lines. It may very well be that fructose could still be a
substrate of interest to the imaging community as was observed in
two recent reports [24,25] and that increased fructose uptake in
breast cancer cells is mediated by one of the other fructose
transporters. Future studies would need to examine if indeed
fructose is taken up better than glucose in vivo in breast cancer
animal models through a biodistribution study using C14 labeled
fructose.
Conclusion
In conclusion, we find no evidence for GLUT 5 over-expression
in breast cancer cells and tissues contrary to previous reports by
others. More studies are needed to determine if radiolabeled
fructose/fructose analogues could be used as metabolic PET
tracers in the imaging of breast.
Table 1. Staining intensities from 40 breast cancer samples
stained with GLUT 5-antibody.
Staining Intensity 0 1 1–22 2 –33 4
Number of Samples 41 2 1 292 10
doi:10.1371/journal.pone.0026902.t001
Figure 5. Immunohistochemistry study of breast tissue. Immunohistochemical staining of breast carcinoma and adjacent normal breast tissue
with Glut5-antibody. A, C and E are infiltrating lobular carcinoma and B, D and F the corresponding normal breast tissue. (Magnification is 40x).
doi:10.1371/journal.pone.0026902.g005
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